SG

LED Lighting, Maintenance and EV Charging Solutions Provider Orion’s Q2’24 Revenue Rose 17% to $20.6M; Maintains 30% Revenue Growth Outlook for FY 2024

Retrieved on: 
Tuesday, November 7, 2023
U.S. Department of Defense Strategy for Operating in Cyberspace, FY, EV, United States Department of Defense, Earnout, SG, Orion, Acquisition, Maintenance, Environment, LED, Growth, ESCO, EPS, Borrowing base, Investment, Energy service company, Pharmaceutical industry, Airline, Bank, Retail, Telescopic sight, European

EV charging solutions revenue rose to $3.4M in Q2’24 vs. $1.2M in Q1’24 and no revenue in the year ago quarter prior to the acquisition of Voltrek.

Key Points: 
  • EV charging solutions revenue rose to $3.4M in Q2’24 vs. $1.2M in Q1’24 and no revenue in the year ago quarter prior to the acquisition of Voltrek.
  • Our Voltrek EV charging solutions revenue rose to $3.4M, reflecting the benefits of investments we have made to position it for accelerating growth and an expanded national reach.
  • Our maintenance services business delivered year-over-year growth, benefiting from a new 3-year agreement with Orion’s largest customer.
  • These include our new TritonProTM LED retrofit high-bay lighting fixtures, as well as our new Harris exterior LED lighting products.

OLAPLEX Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023
SG, Ratio, EBITDA, EPS, GAAP, Disclosure, Real estate

During the third quarter of 2023, the Company experienced a continued lower level of demand for its products versus the third quarter of 2022.

Key Points: 
  • During the third quarter of 2023, the Company experienced a continued lower level of demand for its products versus the third quarter of 2022.
  • As of September 30, 2023, the Company had $429.6 million of cash and cash equivalents, compared to $322.8 million as of December 31, 2022.
  • Inventory at the end of the third quarter 2023 was $112.8 million, compared to $144.4 million at the end of December 2022.
  • The Company updated its guidance for fiscal year 2023 on net sales, adjusted net income and adjusted EBITDA, as set forth below.

Latham Group, Inc. Reports Third Quarter Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Adjustment, Insurance, Fiscal, Public expenditure, SG, EBITDA, Environment, Capital expenditure, ...Continued, Capital, Bookkeeping, Reinsurance, Renewable energy, Pharmaceutical industry

LATHAM, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Latham Group, Inc. (“Latham” or “the Company”) (Nasdaq: SWIM), the largest designer, manufacturer and marketer of in-ground residential swimming pools in North America, Australia and New Zealand, today announced financial results for the third quarter and first nine months of its fiscal year 2023 ended September 30, 2023.

Key Points: 
  • Gross profit for the third quarter of fiscal 2023 was $48.1 million, down $10.7 million or 18.2%, from $58.9 million in the prior year’s third quarter.
  • Adjusted EBITDA for the third quarter of fiscal 2023 was $36.1 million, down $6.2 million or 14.6%, from $42.3 million in the prior year’s third quarter.
  • Capital expenditures totaled $4.9 million in the third quarter of fiscal 2023 compared to $12.3 million in the third quarter of fiscal 2022.
  • Latham has updated its net sales, adjusted EBITDA and capital expenditures guidance for the full year fiscal 2023.

Solo Brands Reports Strong Third Quarter Results

Retrieved on: 
Tuesday, November 7, 2023
Fashion, Lifestyle, Retail, Consumer, Home Goods, Specialty, Line of credit, Nine Months, Brand, NYSE, Three Months, SG, Pressure, EBITDA, GAAP, ISLE, EPS, Marketing, Webcast, Term loan, DTC, Security (finance), Real estate, Fossil fuel, Pet industry, Clothing, Video game, Life insurance, Cryptocurrency

Solo Brands, Inc. (NYSE: DTC) (“Solo Brands” or “the Company”) today announced its financial results for the three and nine month periods ended September 30, 2023.

Key Points: 
  • Solo Brands, Inc. (NYSE: DTC) (“Solo Brands” or “the Company”) today announced its financial results for the three and nine month periods ended September 30, 2023.
  • Brand momentum is encouraging as we grow our retailer relationships,” said John Merris, Chief Executive Officer of Solo Brands.
  • Solo Brands generates healthy EBITDA margins, has low financial leverage, a balanced omnichannel sales approach, and is capital-lite, leading to strong free cash flow.”
    Operating Results for the Three Months Ended September 30, 2023
    Net sales increased 8.0% to $110.3 million compared to $102.2 million in the third quarter of 2022.
  • Adjusted EPS(1) was $0.28 per diluted share for the third quarter of 2023 compared to $0.15 for the third quarter of 2022.

Dutch Bros Inc. Reports Third Quarter 2023 Financial Results and Announces Two New Directors

Retrieved on: 
Tuesday, November 7, 2023
Retail, Restaurant, Bar, Food, Beverage, Adjustment, BROS, Credit Suisse, NYSE, NAPA, Public expenditure, SG, Taylor Morrison, GAAP, Santa Barbara, PetSmart, Politics, Growth, The Duckhorn Portfolio, Gibson, Webcast, Business, University, Gibson Dunn, Columbia Law School, Vulnerability and Risk Committee, Investment, Audit, Amusement park, Video game, Management, Pharmaceutical industry, Cryptocurrency, Security (finance), Online shopping, Fine chemical, Dutch Bros. Coffee, Economics, Q3

Dutch Bros Inc. (NYSE: BROS; “Dutch Bros” or the “Company”), one of the fastest-growing brands in the food service and restaurant industry in the United States by location count, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Dutch Bros Inc. (NYSE: BROS; “Dutch Bros” or the “Company”), one of the fastest-growing brands in the food service and restaurant industry in the United States by location count, today reported financial results for the third quarter ended September 30, 2023.
  • Joth Ricci, Chief Executive Officer of Dutch Bros, stated, “By all accounts, Q3 was a fantastic quarter, and we are extremely pleased with our unit openings, same shop sales, revenue, and profitability results.
  • Dutch Bros is providing the following guidance for the year 2023:
    Our expectation for total system shop openings in 2023 remains unchanged.
  • We will also publish earnings presentation slides related to these financial results on our website https://investors.dutchbros.com under “Events & Presentations”.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Professional Services, Health, FDA, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Biomedical Advanced Research and Development Authority, Research, Security (finance), NMPA, Therapy, Medication, Ganaxolone, SG, Human services, G&A, Marinus, Administration for Strategic Preparedness and Response, National Medical Products Administration, GAAP, Center for Drug Evaluation and Research, BARDA, MAD, Lennox–Gastaut syndrome, Administration, R, Development, RAISE, CDE, Epilepsy, RSE, API, TSC, NDA, U.S. Department of Defense Strategy for Operating in Cyberspace, Office of Inspector General, U.S. Department of Health and Human Services, Investment, Patient, Status epilepticus, Pharmaceutical industry, Fine chemical, Cryptocurrency, CDD

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2023.
  • Dr. Braunstein continued, “We remain acutely focused on advancing our Phase 3 clinical trials in refractory status epilepticus and tuberous sclerosis complex.
  • Net product revenue consists of ZTALMY product sales, which was launched in the U.S. in the third quarter of 2022.
  • Selected Financial Data (in thousands, except share and per share amounts)

Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Adjustment, Ratio, FDA, Risk, Security (finance), United States bankruptcy court, Result, Food, Bankruptcy, Conversation, Pressure, SG, EBITDA, GAAP, Nitric oxide, Research, R, Financial condition report, Ajman Specialty General Hospital, Growth, Attention deficit hyperactivity disorder predominantly inattentive, Shanda, Near-term digital radio, Analysis, The Company, Hospital, Public, Chapter 11, Title 11, United States Code, Food and Drug Administration, Patient, ADHD, Dietary supplement, Pharmaceutical industry, Video game, Fine chemical, Cryptocurrency, Medical device, Mallinckrodt, Terlipressin

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- Mallinckrodt plc (in examinership) (OTCMKTS: MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported its financial results for the third quarter ended September 29, 2023.

Key Points: 
  • Mallinckrodt's net sales in the third quarter of 2023 were $497.0 million, as compared to $465.4 million in the third quarter of 2022.
  • The Company recorded a net loss for the third quarter of $1,724.8 million, as compared to $284.9 million in the third quarter of 2022.
  • Adjusted gross profit as a percentage of sales was 66.3% for the third quarter of 2023, as compared to 66.2% for the third quarter of 2022.
  • Please see "Non-GAAP Financial Measures" included in this release for a discussion of non-GAAP measures and reconciliation of GAAP and non-GAAP financial measures for the third quarter.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sweetgreen, Inc. - SG

Retrieved on: 
Monday, November 6, 2023
NYSE, Prior, SG, News, Pomerantz, LLP, Cryptocurrency, Sweetgreen

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sweetgreen, Inc. (“Sweetgreen” or the “Bank”) (NYSE: SG).

Key Points: 
  • NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sweetgreen, Inc. (“Sweetgreen” or the “Bank”) (NYSE: SG).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Sweetgreen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, November 6, 2023
Complete Response Letter, COGS, CCR8, FDA, Element, Research, Sale, IND, Food, PIN, Biologics license application, Medicare, SG, Cisplatin, Injector, Symantec Endpoint Protection, Surface, Conference, PD-1, GAAP, CHRS, Acquisition, HIV disease progression rates, Exercise, NPC, R, CRL, Adalimumab, Ranibizumab, Neoplasm, Risk, Webcast, Tumor microenvironment, Conference call, Investment, IL-27, BLA, Investigational New Drug, Rare-earth element, Video game, Pharmaceutical industry, Medical device, Online shopping, Q2

REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2023, and recent business highlights:

Key Points: 
  • – Conference call today at 5:00 p.m. Eastern Time –
    REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2023, and recent business highlights:
    CIMERLI® (ranibizumab-eqrn) net product sales increased in the third quarter 2023 to $40.0 million compared to $26.7 million in the second quarter.
  • UDENYCA® (pegfilgrastim-cbqv) net product sales increased in the third quarter 2023 to $33.0 million compared to $31.7 million in the second quarter.
  • Market share grew to 16.5% in the third quarter 2023, an increase of 4.3 market share percentage points compared to the prior quarter.
  • Coherus anticipates demand will continue to rise with significantly improved commercial and Medicare Advantage formulary coverage in the fourth quarter of 2023 and in 2024.

NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

Retrieved on: 
Monday, November 6, 2023
FDA, Insurance, Sale, Neurosurgery, Physician, RNS, SG, Telephone, CEC, Conference, Project, TRM, Research, Growth, Marketing, Webcast, Partnership, Lender option borrower option, Epilepsy, EEG, Investment, Patient, Responsive neurostimulation device, Pharmaceutical industry, Rare-earth element, Video game, Nursing

MOUNTAIN VIEW, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Achieved total revenue of $16.4 million for the third quarter of 2023, representing a 47% increase over the third quarter of 2022.
  • Gross margin for the third quarter of 2023 was 74.5% compared to 71.4% in the third quarter of 2022 and 72.5% in the second quarter of 2023.
  • Total cash burn in the third quarter of 2023 was $2.2 million, a reduction from $4 million in the second quarter of 2023 and $9.8 million in the first quarter of 2023.
  • NeuroPace will host a conference call to discuss the third quarter 2023 financial results after market close on Monday, November 6, 2023, at 4:30 P.M. Eastern Time.